IMAB – i-mab - american depositary shares (US:NASDAQ)
Stock Stats
News
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases [Yahoo! Finance]
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Form 6-K I-Mab For: Apr 04
Form 20-F I-Mab For: Dec 31
Form 6-K I-Mab For: Apr 03
Form 6-K I-Mab For: Mar 21
Form 6-K I-Mab For: Mar 07
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.